Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The TANTALUS® II for the Treatment of Type 2 Diabetes (Crossover)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
MetaCure (USA), Inc.
ClinicalTrials.gov Identifier:
NCT01303302
First received: February 23, 2011
Last updated: May 27, 2014
Last verified: May 2014

February 23, 2011
May 27, 2014
April 2008
May 2015   (final data collection date for primary outcome measure)
Comparison of the differences in HbA1c levels [ Time Frame: One year ] [ Designated as safety issue: No ]
Comparison of the differences in HbA1c levels between treatment and control groups between changes occurred during period 2 to period 3
Same as current
Complete list of historical versions of study NCT01303302 on ClinicalTrials.gov Archive Site
Improvement in weigth and metabolic parameters [ Time Frame: One year ] [ Designated as safety issue: Yes ]
  • Trends in weight loss will be of a reduction in weight during periods 2 and 3.
  • Trends in improvement in metabolic parameters such as waist circumference, blood pressure and lipids occurred during period 2 to period 3.
  • Difference in device related Adverse Events between treatment and control groups between periods of active and inactive therapy.
Same as current
Not Provided
Not Provided
 
The TANTALUS® II for the Treatment of Type 2 Diabetes
The TANTALUS® II for the Treatment of Type 2 Diabetes: A Single-Blind Cross-Over Study

Evaluation of the safety and efficacy of gastric contractility modulation (GCM) stimulation using the TANTALUS System in the improvement of glycemic control measured by changes in HbA1c. Effects of GCM on weight loss and associated co-morbid conditions will also be evaluated

This is a multi-center, single blind, randomized, cross-over study. Subject enrollment will continue until forty (40) eligible participants have been randomized into one of the two groups. Subjects will undergo baseline valuation (Visit 1) during which the stability of their glycemic parameters, medical treatment and medical condition will be assessed. Subjects meeting all inclusion/exclusion criteria at Visit 2 will be implanted. Approximately three days prior to their implantation, subjects will be seen for their 'pre-implant' medical evaluation (Visit 3). One week after implant (Visit 5, Week 1)subjects will be randomized into one of two groups (A and B).

"Group A" subjects will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for the first 24 week period (Period 1). At Visit 10, (week 25 and end of Period 1), Group A subjects will have their devices turned "OFF" for the next 24 weeks period (Period 2). At Visit 15, (week 49 and end of Period 2), Group A subjects will have their devices turned "On" for the next 24 weeks period (Period 3) "Group B" subjects will not have their device activated for the first 24 weeks (Period 1) of their study. At Visit 10 (week 25 end of Period 1), Group B subjects devices will have their device turned "ON" (i.e. activated to deliver CGM signals) for the 24 weeks period (Period 2). At Visit 15, (week 49 and end of Period 2), Group B subjects will have their devices turned "OFF" for the next 24 weeks period (Period 3).

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Device: Tantalus System
    The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
    Other Name: TANTALUS II
  • Device: TANTALUS system
    The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
    Other Name: TANTALUS II
  • Active Comparator: GCM stimulation
    The patient will be implanted with a gastric contractility modulation (GCM) stimulation system using the TANTALUS System for treatment of type 2 diabetic patients.
    Intervention: Device: Tantalus System
  • Sham Comparator: Device off
    The TANTALUS System is implanted but is off
    Intervention: Device: TANTALUS system
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
May 2015
May 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female subjects 18 through 70 years of age
  • Body mass index >=28 and <=45 (kg/m2)
  • Type 2 diabetes duration more than 6 month
  • Type 2 diabetic sublecys treated with oral anti-diabetic agents
  • Stable anti-diabetic medication for at least 3 month prior to enrollment
  • HbA1c >=7.5% and <=9.5% on visit 1; subjects with T2DM duration .10 years should have <=9.0% at visit 1
  • Stable HbA1c, defined as no significant change (variation <=0.5%)between a historical value recorded in the subject's medical record with in 3 month prior to enrollment and the HbA1c gathered at visit 1
  • Fasting blood glucose >120 and < 240 mg/dl on visit 1; subjects with T2DM duration > 10 yaers should have .120 ans<=180 mg/dl at visit 1
  • Women with child bearing potential (i.e, not post menopausal or surgically sterilized) must agree to use adequate birth control methods
  • Stable weight, defined as no significant weight change (variation <5%)within three months prior to enrollment
  • If taking these medication, stable anti-hepertensive and lipid-lpwering medication for at least one month prior to enrollment
  • If subject is under unti-depressant medication the treatment needs to be stable for at least six month prior to enrollment
  • Wllingness to refrain from using prescription, over the counter or herbal weight loss product for the duration of the trial
  • Ability and willingliness to perform required study and data collection procedures and adhere to operating requirements of the TANTALUS II Syatem
  • Alert, mentally competant, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
  • Able to provide voluntary informed consent

Exclusion Criteria:

  • Insulin therapy
  • Taking GLP-1 analogue, such as exenatide (Byette) in the last 3 month before enrollment Taking medication known to affec gastric mobility such as narcotics (chronic use) and anticholinergics/antispasmodics
  • Use of prescription, over the counter or herbal weight loss product or obesity drugs during the past two month
  • Experiencing sever and progressing diabetic complications (i.e retinopathy not stabilized, nephropathy with macroalbuminuria)
  • Prior wound healing problems
  • Diagnosed with past or present psychiatric condition that may impair his or her ability to comply with the study procedure
  • Use of anti-pchichotic medication
  • Diagnosed with an eating disorder such as bulimia or binge eating
  • Obesity due to endocrinopathy (e.g.Cushing disease, Hypothyroidism)
  • Hiatal hernia requiring surgical repair or paraesophageal hernia
  • Pregnant or lactating Diagnosed with impared liver function (liver enzyms 3 times graeted than normal)
  • Any prior bariatric surgery
  • Ant history of pancreattitis Any history of peptic ulcer disease within 5 years of enrollemnt Diagnosed with gastroparesis or GI mobility disorder Use of active medical device (either implantable or external) such as ICD, pacemaker, drug infusion device, or neurostimulator (either implantable or worn) Subject using an external active device who are able anf willing to avoid use of the device during the study may be enrolled.
  • Cardiac history that physician feels should exclude the subject from the study.
  • Use of anotherc investigational device agent in the 30 dayes prior to enrollemnt
  • A history of life threatening diseas within 5 years of enrollment
  • Change in diabetic medication from between visit 1 and visit 3
  • Any additional condition(S) that in the investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Germany,   Italy,   Poland
 
NCT01303302
MC CP TAN2007-032, Cross-over
Yes
MetaCure (USA), Inc.
MetaCure (USA), Inc.
Not Provided
Study Director: Walid Hadda, PhD Metacure
MetaCure (USA), Inc.
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP